#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA5053070	F	Antiproliferative activity against doxycycline-induced NGLY1 knocked down human UACC-257 cells at 20 uM in presence of dacarbazine assessed as decrease in growth inhibition after 72 hrs by MTT assay	Homo sapiens	4		cell-based format	Patent Bioactivity Data
2.	ALA5053071	F	Antiproliferative activity against doxycycline-induced NGLY1 knocked down human Malme-3M cells at 20 uM in presence of dacarbazine assessed as decrease in growth inhibition after 72 hrs by MTT assay	Homo sapiens	1		cell-based format	Patent Bioactivity Data
3.	ALA5053072	B	Inhibition of NGLY1 in human HEK293T cells at 200 uM assessed as retention of N-glycans on full-length NFE2L1 measured by electrophoretic mobility shift assay	Homo sapiens	1		cell-based format	Patent Bioactivity Data
4.	ALA5053073	F	Antiproliferative activity against human UACC-257 cells at 10 to 1000 uM assessed as decrease in cell viability	Homo sapiens	4		cell-based format	Patent Bioactivity Data
5.	ALA5053074	F	Antiproliferative activity against human SK-MEL-2 cells at 10 to 1000 uM assessed as decrease in cell viability	Homo sapiens	4		cell-based format	Patent Bioactivity Data
6.	ALA5053075	T	Antiproliferative activity against human HDF51 cells at 10 to 1000 uM assessed as decrease in cell viability	Homo sapiens	4		cell-based format	Patent Bioactivity Data
7.	ALA5053076	T	Antiproliferative activity against human HDF418 cells at 10 to 1000 uM assessed as decrease in cell viability	Homo sapiens	4		cell-based format	Patent Bioactivity Data
8.	ALA5053077	B	Inhibition of NGLY1 in human UACC-257 cells at 200 uM assessed as increase in IFN-beta1 production measured after 48 hrs	Homo sapiens	3		cell-based format	Patent Bioactivity Data
9.	ALA5053078	B	Inhibition of NGLY1 in human UACC-257 cells at 200 uM assessed as increase in IL-29 production measured after 48 hrs	Homo sapiens	3		cell-based format	Patent Bioactivity Data
10.	ALA5053079	B	Inhibition of NGLY1 in human SK-MEL-2 cells at 200 uM assessed as increase in IFN-beta1 production measured after 48 hrs	Homo sapiens	3		cell-based format	Patent Bioactivity Data
11.	ALA5053080	B	Inhibition of NGLY1 in human SK-MEL-2 cells at 200 uM assessed as increase in IL-29 production measured after 48 hrs	Homo sapiens	3		cell-based format	Patent Bioactivity Data
12.	ALA5053084	F	Antiproliferative activity against human SK-MEL-2 cells assessed as decrease in cell viability in presence of bortezomib	Homo sapiens	1		cell-based format	Patent Bioactivity Data